Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Squarepoint Ops LLC

Squarepoint Ops LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 58.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 101,417 shares of the company's stock after buying an additional 37,533 shares during the period. Squarepoint Ops LLC owned 0.10% of Intellia Therapeutics worth $1,183,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Barclays PLC lifted its holdings in shares of Intellia Therapeutics by 17.7% in the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock worth $6,017,000 after acquiring an additional 44,022 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Intellia Therapeutics by 85.7% in the 4th quarter. SG Americas Securities LLC now owns 44,838 shares of the company's stock worth $523,000 after acquiring an additional 20,694 shares during the last quarter. KBC Group NV lifted its holdings in shares of Intellia Therapeutics by 62.4% in the 4th quarter. KBC Group NV now owns 6,093 shares of the company's stock worth $71,000 after acquiring an additional 2,340 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Intellia Therapeutics by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company's stock worth $252,000 after acquiring an additional 2,059 shares during the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of Intellia Therapeutics in the 4th quarter worth approximately $185,000. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Trading Down 6.2%

NASDAQ:NTLA traded down $0.46 during midday trading on Friday, hitting $6.99. 8,839,884 shares of the company were exchanged, compared to its average volume of 2,692,830. The company has a fifty day simple moving average of $7.93 and a 200 day simple moving average of $10.23. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The company has a market capitalization of $724.05 million, a PE ratio of -1.28 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. During the same quarter in the prior year, the business earned ($1.12) earnings per share. Intellia Therapeutics's revenue was down 42.6% compared to the same quarter last year. As a group, equities research analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on NTLA shares. Truist Financial decreased their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective on the stock in a report on Monday, April 21st. Citigroup reduced their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Wall Street Zen raised shares of Intellia Therapeutics to a "sell" rating in a research report on Monday, March 3rd. Finally, Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Intellia Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $36.75.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.